About BioVascular

About company

BioVascular is a clinical stage privately held biotechnology company developing “first in class” products for platelet mediated cardiovascular diseases. BioVascular’s initial product, saratin, is a polypeptide produced by recombinant means in yeast. This product was discovered by and licensed from Merck KGaA. BioVascular is conducting human clinical trials of saratin for use in hemodialysis access graft and peripheral artery grafts to reduce intimal hyperplasia, which can lead to failure of the graft.